Free Trial

Structure Therapeutics (GPCR) Competitors

Structure Therapeutics logo
$19.61 +0.24 (+1.24%)
Closing price 04:00 PM Eastern
Extended Trading
$19.92 +0.32 (+1.61%)
As of 05:12 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

GPCR vs. PTCT, MENS, MLTX, MTSR, PTGX, APLS, SRRK, MIRM, MOR, and NAMS

Should you be buying Structure Therapeutics stock or one of its competitors? The main competitors of Structure Therapeutics include PTC Therapeutics (PTCT), Jyong Biotech (MENS), MoonLake Immunotherapeutics (MLTX), Metsera (MTSR), Protagonist Therapeutics (PTGX), Apellis Pharmaceuticals (APLS), Scholar Rock (SRRK), Mirum Pharmaceuticals (MIRM), MorphoSys (MOR), and NewAmsterdam Pharma (NAMS). These companies are all part of the "pharmaceutical products" industry.

Structure Therapeutics vs. Its Competitors

PTC Therapeutics (NASDAQ:PTCT) and Structure Therapeutics (NASDAQ:GPCR) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, valuation, earnings, risk, dividends, analyst recommendations, profitability and media sentiment.

In the previous week, PTC Therapeutics had 33 more articles in the media than Structure Therapeutics. MarketBeat recorded 37 mentions for PTC Therapeutics and 4 mentions for Structure Therapeutics. Structure Therapeutics' average media sentiment score of 0.48 beat PTC Therapeutics' score of 0.04 indicating that Structure Therapeutics is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
PTC Therapeutics
8 Very Positive mention(s)
3 Positive mention(s)
7 Neutral mention(s)
7 Negative mention(s)
1 Very Negative mention(s)
Neutral
Structure Therapeutics
1 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
1 Negative mention(s)
1 Very Negative mention(s)
Neutral

PTC Therapeutics has a net margin of 35.65% compared to Structure Therapeutics' net margin of 0.00%. Structure Therapeutics' return on equity of -21.31% beat PTC Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
PTC Therapeutics35.65% -106.31% 30.61%
Structure Therapeutics N/A -21.31%-20.34%

PTC Therapeutics presently has a consensus target price of $69.15, suggesting a potential upside of 36.75%. Structure Therapeutics has a consensus target price of $75.71, suggesting a potential upside of 286.10%. Given Structure Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Structure Therapeutics is more favorable than PTC Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
PTC Therapeutics
1 Sell rating(s)
5 Hold rating(s)
9 Buy rating(s)
1 Strong Buy rating(s)
2.63
Structure Therapeutics
0 Sell rating(s)
0 Hold rating(s)
8 Buy rating(s)
0 Strong Buy rating(s)
3.00

PTC Therapeutics has a beta of 0.54, suggesting that its share price is 46% less volatile than the S&P 500. Comparatively, Structure Therapeutics has a beta of -1.89, suggesting that its share price is 289% less volatile than the S&P 500.

91.8% of Structure Therapeutics shares are owned by institutional investors. 5.5% of PTC Therapeutics shares are owned by insiders. Comparatively, 5.6% of Structure Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Structure Therapeutics has lower revenue, but higher earnings than PTC Therapeutics. Structure Therapeutics is trading at a lower price-to-earnings ratio than PTC Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
PTC Therapeutics$806.78M4.98-$363.30M$6.977.26
Structure TherapeuticsN/AN/A-$122.53M-$1.05-18.68

Summary

PTC Therapeutics beats Structure Therapeutics on 8 of the 15 factors compared between the two stocks.

Get Structure Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for GPCR and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding GPCR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

GPCR vs. The Competition

MetricStructure TherapeuticsMED IndustryMedical SectorNASDAQ Exchange
Market Cap$1.12B$3.09B$5.82B$9.73B
Dividend YieldN/A2.23%3.84%4.09%
P/E RatioN/A21.1431.1525.97
Price / SalesN/A401.49476.16171.70
Price / CashN/A43.0937.1558.38
Price / Book1.468.079.116.39
Net Income-$122.53M-$54.72M$3.26B$265.66M
7 Day Performance-2.53%2.62%2.11%1.98%
1 Month Performance7.81%7.63%5.12%1.33%
1 Year Performance-49.91%13.11%31.25%21.15%

Structure Therapeutics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
GPCR
Structure Therapeutics
2.529 of 5 stars
$19.61
+1.2%
$75.71
+286.1%
-51.1%$1.12BN/A0.00136
PTCT
PTC Therapeutics
4.4522 of 5 stars
$43.30
-4.6%
$70.15
+62.0%
+44.2%$3.60B$806.78M6.211,410Trending News
Analyst Forecast
Analyst Revision
MENS
Jyong Biotech
N/A$49.56
+9.3%
N/AN/A$3.45BN/A0.0031News Coverage
High Trading Volume
MLTX
MoonLake Immunotherapeutics
1.6383 of 5 stars
$53.38
+1.9%
$74.43
+39.4%
+9.8%$3.35BN/A-19.202
MTSR
Metsera
N/A$30.14
-0.9%
$55.00
+82.5%
N/A$3.19BN/A0.0081
PTGX
Protagonist Therapeutics
1.877 of 5 stars
$53.75
+5.2%
$67.20
+25.0%
+34.9%$3.18B$434.43M76.79120Positive News
APLS
Apellis Pharmaceuticals
4.159 of 5 stars
$23.85
-2.1%
$34.12
+43.1%
-30.7%$3.08B$781.37M-13.10770News Coverage
Insider Trade
Short Interest ↑
SRRK
Scholar Rock
4.5802 of 5 stars
$31.46
-1.5%
$45.14
+43.5%
+273.5%$3.07B$33.19M-10.81140News Coverage
Analyst Forecast
MIRM
Mirum Pharmaceuticals
3.5229 of 5 stars
$65.87
+9.8%
$74.13
+12.5%
+67.5%$3.01B$336.89M-54.44140Positive News
High Trading Volume
MOR
MorphoSys
N/A$18.96
flat
N/AN/A$2.86B$238.28M-5.45730Positive News
NAMS
NewAmsterdam Pharma
3.4719 of 5 stars
$24.37
-3.7%
$41.20
+69.1%
+50.2%$2.84B$45.56M-15.044

Related Companies and Tools


This page (NASDAQ:GPCR) was last updated on 8/22/2025 by MarketBeat.com Staff
From Our Partners